Simulated Clinical Trial for Nattokinase, Curcumin, Bromelain, and Ivermectin for Long COVID or Spike Protein Syndrome (2025)

Currently, there are no published simulated clinical trials (e.g., in silico clinical trial models or virtual patient cohort studies) specifically evaluating the combination of nattokinase, curcumin, bromelain, and ivermectin for Long COVID or spike protein syndrome. However, in silico studies, in vitro research, and observational data provide a foundation for designing such a trial. Below, we outline a hypothetical framework for a simulated clinical trial based on existing evidence, proposed mechanisms, and computational modeling approaches. This framework incorporates insights from in silico and preliminary studies, addresses gaps, and aligns with the query's focus on Long COVID and spike protein-related syndromes. Simulated (In Silico) Clinical Trial Design Objective: To evaluate the efficacy and safety of a combination regimen of nattokinase, curcumin, bromelain, and ivermectin in reducing symptoms of Long COVID or spike protein syndrome (e.g., fatigue, brain fog, cardiovascula...